To Register for the 16th International Symposium on Translational Research in Oncology please click here
For printable version of programme please click here: 18.09.23 Programme – 16th International Symposium on Translational Research in Oncology
To register for the AICRI – Vision and Showcase event click here
16th International Symposium on Translational Research in Oncology
Wednesday, 27th September 2023, Lansdowne Suite
09.00 – 12.30 AICRI Showcase To register for the AICRI showcase click here
Registration for the Symposium from 12:30 CPD:3 external credits
13:30 – 13.45 Welcome and Introduction – Prof John Crown, St. Vincent’s Hospital Group, Dublin
TARGETED THERAPIES IN CANCER I: Session Chair – Prof. Sara Hurvitz, Fred Hutchinson Cancer Center
13:45 – 14:15 HER2 as a therapeutic target in HER2-normal breast cancer
Prof. Sara Hurvitz, Senior Vice President, Clinical Research Division, Fred Hutchinson Cancer Center, Head, Division of Hematology/Oncology, University of Washington
14:15 – 14:45 Targeting Estrogen Receptor in breast cancer: old target, new drugs
Dr. Aditya Bardia, Director, Breast Cancer Research, Medical Oncology, Massachusetts General Hospital Cancer Center, Associate Professor, Harvard Medical School, Boston
14:45 – 15:15 HER2+ GP2 vaccine and the FLAMINGO Phase III trial
Mr. Snehal Patel, CEO, Greenwich Lifesciences
15:15 – 15:30 Coffee break
TARGETED THERAPIES IN CANCER II: Session Chair – Prof. Sara Hurvitz, Fred Hutchinson Cancer Center
15:30 – 16:15 Patient-derived models of breast cancer for drug discovery and precision medicine
Dr. Alana Welm, Huntsman Cancer Institute, University of Utah, Salt Lake City
16:15 – 16:45 TPD squared – Dual-Precision Targeted Protein Degradation For Oncology Therapeutics Discovery and Development
Dr. James Palacino, VP/Head of Biology, Orum Therapeutics
16:45 – 17:15 Topic: CDK inhibitors and the NATALEE trial
Dr. Dennis J. Slamon, 2019 Lasker Award Winner, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women’s Cancer Research Program at JCCC. Professor of Medicine, Chief, Division of Hematology/Oncology UCLA.
Thursday, 28th September 2023, Lansdowne Suite, Herbert Park Hotel
Registration from 08:30 CPD: 6 external credits
TUMOUR MICRO-ENVIRONMENT I: Session Chair – Prof. Bob Kerbel, University of Toronto
09:00 – 09:30 Modulation of the tumor associated fibronectin ECM to enhance efficacy of immune checkpoint blockade
Prof Robert Kerbel & Dr. Kabir Khan, Sunnybrook Research Institute, University of Toronto
09:30 – 10:00 Overcoming endothelial cell anergy for improvement of immunotherapy against cancer
Prof Arjan Griffioen, Head of the Angiogenesis Laboratory, Amsterdam UMC
10:00 – 10:30 Orally available RGD-mimetic and enhancement of immunotherapy efficacy
Prof Kairbaan Hodivala Dilke, Professor of Tumour Microenvironment, Queen Mary University of London, and Deputy Director of Barts Cancer Institute.
10:30 – 10:45 Coffee break
TUMOUR MICRO-ENVIRONMENT II: Session Chair – Prof. Bob Kerbel, University of Toronto
10:45 – 11:15 Brain metastasis in the era of immunotherapy: implications for sequential immunotherapy-based combination therapy
Prof Yuval Shaked, Dept of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion, Israel. Director of the Rappaport-Technion Integrated Cancer Center
11.15 – 11:45 Control of malignant properties by functionally and spatially distinct cancer-associated fibroblasts
Professor Kristian Pietras, Division of Translational Cancer Research, Lund University Cancer Centre
11:45 – 12:15 Extracellular Vesicles in the Tumour Microenvironment
Prof Lorraine O’Driscoll, School of Pharmacy & Pharmaceutical Sciences, Panoz Institute & Trinity Biomedical Sciences Institute & Research Director, Trinity St. James’s Cancer Institute, Trinity College Dublin
12:15 – 13:00 Normalizing the tumor microenvironment to improve immunotherapy of brain tumors: Emerging insights and strategies
Prof. Rakesh Jain, National Medal of Science Awardee 2013, Andrew Werk Cook Professor of Tumor Biology, Massachusetts General Hospital, Harvard Medical School & Director E.L. Steele Laboratories for Tumor Biology, Massachusetts General Hospital.
13:00 – 14:00 Lunch
Targeting Difficult to Drug Genes for Cancer Therapy: Session Chair – Prof Michael J. Duffy, St. Vincent’s University Hospital/University College Dublin
14:00 – 14:30 Targeting MYC: A Dual Effect on Both Cancer Cells and Tumor Microenvironment
Prof Michael J. Duffy, Clinical Research Centre, St. Vincent’s University Hospital, Dublin.
14:30 – 15:00 Biomarker driven development of Brigimadlin, a MDM2-p53 antagonist restoring p53 activity
Dr. Michael Teufel, Exec Dir Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim
15:00 – 15:30 Combination strategies to potentiate the impact of KRAS inhibitors
Dr. Miriam Molina-Arcas, Oncogene Biology Laboratory, The Francis Crick Institute
15:30 – 15:45 Coffee break
Novel Targeted therapies: Session Chair – Prof Denis Collins, Dublin City University
15:45 – 16.15 Development of a novel therapeutic mAb and ADC for CLDN18.2
Dr. Neil O’Brien, Adj Associate Professor, Dept of Medicine, Division of Hematology/Oncology, UCLA
16:15 – 16:45 Selective Therapies for Metastatic Tumor Cells
Prof Bruce Zetter, Charles Nowiszewski Professor of Cancer Biology, Harvard
16:45 – 17:15 Evolving insights into biomarkers and treatment of hepatocellular carcinoma
Prof. Richard Finn, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA.
17:15 – 17:45 Development and characterisation of an anti-Claudin-6 (CLDN6) ADC for the treatment of CLDN6 positive cancer
Dr. Martina McDermott, Adj Assoc Prof, Dept of Medicine, Division of Hematology/Oncology, UCLA ______________________________________________________________
Friday 29th September 2023, Lansdowne Suite, Herbert Park Hotel
Registration from 8:30 CPD: 4 external credits
CANCER IMMUNOTHERAPY I – exploiting immune cells: Session Chair – Prof. Mario Sznol, Yale
09:00 – 09:30 DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates anti-tumor immunity
Dr. Michael Dougan, Massachusetts General Hospital, Harvard Medical School
09:30 – 10:00 Novel Biomarker Discovery for NX-1607: Clinical Insights into a First-in-Class Oral CBL-B Inhibitor for Advanced Malignancies
Dr. Sarah Whelan, Associate Director, Translational Medicine, Nurix Therapeutics
10:00 – 10:30 ACTengine® IMA203 TCR-T: Unleashing the Potential of Targeting PRAME in Solid Tumors
Prof. Dr. med Oliver Ebert, Senior Director, Head of Clinical Development, Immatics
10:30 – 11:00 Cancer cell metabolomics and immunotherapy resistance
Prof. Ken O’ Bryne, Professor of Medical Oncology, Queensland University of Technology
11:00 – 11:15 Coffee break
CANCER IMMUNOTHERAPY II: Session Chair – Prof. Mario Sznol, Yale
11:15-11:45 Cis-targeting of IL-2 and IL-21 cytokines to CD8+ T cells to improve immunotherapies for cancer
Dr. Ivana Djuretic, Chief Scientific Officer, Asher Biotherapeutics
11:45 – 12:15 Development of XTX301, a bioengineered masked, tumor-activated IL-12: unleashing the potent cytokine in the tumor microenvironment
Dr. Katarina Luptakova, MD, Senior Vice President, Medical, Xilio Therapeutics
12:15 – 12:45 New Strategies in Immuno-Oncology: Tumor-directed Oncolytic Immunotherapy (TOI)
Dr. Giuseppe Gullo, Executive Medical Director, Clinical Development, Replimune
12:45 – 13:00 Q & A
13:00 – 14:00 Lunch
Novel targeted drugs & biomarkers: Session Chair – Prof William Gallagher, University College Dublin
14:00 – 14:30 Cancer as a combinatorial challenge
Dr. Lajos Pusztai, Professor of Medicine, Yale University and Director of Breast Cancer Translational Research and Co-Director of the Cancer Center Genomics, Genetics, and Epigenetics Program
14:30 – 15:00 Targeting mediator kinases in prostate and breast cancers
Prof Igor Roninson, CSO, Senex Biotechnology & Prof Eugenia Broude, University of South Carolina
15:00 – 15:30 The role of MRD detection and quantitation in solid tumors
Dr Minetta Liu, Chief Medical Officer, Natera
15:30 – 15:45 Coffee break
Novel targeted drugs & biomarkers II: Session Chair – Prof John Crown, St Vincent’s Hospital
15:45 – 16:15 Understanding TIL therapy for metastatic melanoma
Prof John Haanen, Medical Oncology Dept. Netherlands Cancer Institute
16:15 – 16:45 A Phase 1/2 Study of a First-in-Human Immune-Stimulating Antibody Conjugate (ISAC) BDC-1001 in Patients with Advanced HER2-Expressing Solid Tumors (NCT04278144)
Dr. Mark Pegram, Susy Yuan-Huey Hung Prof Med Oncology, Stanford University School of Medicine
16:45 – 17:15 Topic: Fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma
Prof. John Crown, Consultant Medical Oncologist, St Vincent’s Hospital, Dublin; Professor of Oncology, University College Dublin; Thomas Baldwin Chair of Translational Oncology, Dublin City University
As a result of many years of collaborative research by CCRT and The Caroline Foundation funded researchers based in the NICB in DCU we are delighted to announce that, as a result of this research, the first-in-world, Caroline-1 clinical trial, will commence this month at St. Vincent’s University Hospital under the leadership of Professor John Crown. Please see the press release below for further information.
A new drug combination to treat women with metastatic HER2-positive breast cancer that is based on prior preclinical studies from Dublin City University will enter clinical development in a Phase 1 clinical trial named CAROLINE-1, which will commence later this month.
Researchers at DCU’s National Institute for Cellular Biotechnology (NICB) have previously demonstrated the benefit of combining neratinib, an irreversible pan-HER kinase inhibitor, with standard HER2 antibody therapies, trastuzumab and pertuzumab, in laboratory models. This work has been carried out in collaboration with Puma Biotechnology, Inc., a U.S.-based biopharmaceutical company.
Ireland will become the first country to assess the new combination in women with metastatic HER2-positive breast cancer. The aim of the investigation is to improve on the response currently achieved with standard treatments.
HER2-positive breast cancer accounts for approximately 560 of the 2,500 new breast cancer cases diagnosed in Ireland each year. About 15% of these patients will develop metastatic disease. While the treatment options for patients where this disease has spread are successful for some, for many patients the disease returns. The Caroline-1 study is the first step in the development of a new combination for those patients. The focus of the Phase 1 clinical trial is to confirm the treatment is safe and tolerable and, once this is shown, a Phase 2 clinical trial will look closely at the ability of the new combination to successfully control this cancer.
Explaining the background to the breakthrough, Dr. Denis Collins said,
“This development has been a truly translational process and is the culmination of many years’ work by researchers based in the NICB, most notably Dr. Norma O’Donovan and funders Cancer Clinical Research Trust, The Caroline Foundation and BreastPredict. We found that adding neratinib to existing HER2 antibody therapies improved the anti-cancer effect in the laboratory setting and this provided a compelling rationale for examination in the clinic.”
The CAROLINE-1 study is sponsored by Puma Biotechnology, Inc. and led by Professor John Crown of St. Vincent’s University Hospital, who was recently re-appointed as the Thomas Baldwin Chair of Translational Medicine at DCU.
Commenting on the upcoming clinical trial, Professor Crown said,
“This Phase 1 clinical trial will be conducted in women who have metastatic HER2-positive breast cancer. Whilst women with this disease usually respond well initially to treatment, their response is typically not permanent and the disease will likely return. We hope that this drug combination will prolong the time until a women’s disease returns.
“This is an exciting accomplishment, as the trial is based on the work we conducted in our lab at DCU,” added Professor Crown. “We have worked with Puma Biotechnology, Clinical Oncology Development Europe and Saint Vincent’s University Hospital to bring the first-in-world CAROLINE-1 study to Ireland.
CAROLINE-1 is named for Caroline Dwyer-Hickey who tragically passed away as a result of metastatic breast cancer. The Caroline Foundation was set up in her honour and supports the laboratory work at DCU, which has led to this trial. Our hope is that this trial will improve the treatment options available to women with metastatic HER2-positive breast cancer.”